Mortality among urban drug users and the impact of highly active antiretroviral therapy.
暂无分享,去创建一个
[1] D. Bangsberg,et al. Antiretroviral Therapy, Hepatitis C Virus, and AIDS Mortality Among San Francisco's Homeless and Marginally Housed , 2005, Journal of acquired immune deficiency syndromes.
[2] R. Chaisson,et al. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy , 2001, AIDS.
[3] A Muñoz,et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.
[4] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[5] D. Vlahov,et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. , 2004, The Journal of infectious diseases.
[6] Y. Lo,et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] L. Kalish,et al. Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease , 2001, Annals of Internal Medicine.
[8] Anne M Johnson,et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. , 1999, Journal of acquired immune deficiency syndromes.
[9] S. Galea,et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. , 2005, American journal of epidemiology.
[10] V. M. Shadle,et al. Self-reported antiretroviral therapy in injection drug users. , 1998, JAMA.
[11] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[12] B. Yip,et al. Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.
[13] P. Selwyn,et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. , 1989, The New England journal of medicine.
[14] Mardge H. Cohen,et al. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. , 2000, Archives of internal medicine.
[15] S. Holmberg,et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993–1999 , 2003, Journal of Urban Health.